Selected angiogenic cytokines in systemic lupus erythematosus patients

References

• D'Cruz D. Vasculitis in systemic lupus erythematosus. Lupus 1998; 7: 270–274
   PubMed Web of Science ®Google Scholar
• Cieślik P, Hrycek A, Kłuciński P. Vasculopathy and vasculitis in systemic lupus erythematosus. Pol Arch Med Wewn 2008; 118: 57–62
   PubMedGoogle Scholar
• Robak E, Woźnicka A, Sysa-Jędrzejowska A, Stępień H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002; 11: 348–355
   PubMedGoogle Scholar
• Heshmat NM, El-Kerdany TH. Serum levels of vascular endothelial growth factor in children and adolescents with systemic lupus erythematosus. Pediatr Allergy Immunol 2007; 18: 346–353
   PubMedGoogle Scholar
• Robak E, Kulczycka L, Tomczak J, Sysa-Jędrzejowska A. The role of angiogenesic cyto-kines in systemic lupus erythematosus pathogenesis. Acta Haematol Pol 2006; 37: 47–59
   Google Scholar
• Navarro C, Candia-Zúňiga L, Silveria LH, Ruiz V, Gaxiola M, Avila MC, Amigo MC. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus 2002; 11: 21–24
   PubMed Web of Science ®Google Scholar
• Sezar O, Jakob Ch, Eucker J, Niemöller K, Gatz F, Wernecke K-D, Possinger K. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001; 66: 83–88
   PubMedGoogle Scholar
• Jośko J, Gwóźdź B, Jędrzejowska-Szypułka H, Hendryk H. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000; 6: 1047–1052
   PubMedGoogle Scholar
• Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentration of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998; 139: 1049–1051
   PubMed Web of Science ®Google Scholar
• Robak E, Woźniacka A, Sysa-Jędrzejowska A, Stępień H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cyt Netw 2001; 12: 445–452
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
   PubMed Web of Science ®Google Scholar
• Kuryliszyn-Moskal A, Klimuk PA, Sierakowski S, Ciołkiewicz M. Vascular endothelial growth factor in systemic lupus erythematosus: Relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp 2007; 55: 179–185
   PubMedGoogle Scholar
• Robak E, Sysa-Jędrzejowska A, Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm 2003; 12: 293–298
   PubMedGoogle Scholar
• Robak E, Kulczycka L, Sysa-Jędrzejowsla A, Woerzbowska A, Robak T. Circulating proangiogenic molecules PIGF, SDF-1 nad sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 2007; 18: 181–187
   PubMedGoogle Scholar
• Yamasaki M. ETS family of transcription factors and the vascular system. In: Vascular complications in human disease. Springer-Verlag, London 2008
   Google Scholar
• Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705–10709
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Iwata K, Shibuya M. Soluble Fit-1(soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Comm 2002; 291: 554–559
   PubMed Web of Science ®Google Scholar
• Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Rüegg C. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. Int J Cancer 2006; 118: 755–764
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Fitschen J, Martinet N, Schlaak M, Müller-Quernheim J. Serum level of soluble tumor necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J Intern Med 2000; 248: 33–41
   PubMed Web of Science ®Google Scholar
• Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008; 10: 202, Epub 2008 Jan 23
   PubMed Web of Science ®Google Scholar
• Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheum 1996; 35: 1067–1074
   PubMedGoogle Scholar
• Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK, Abdel-Khalek E, El-Shafey EM, Abo-Zenah H. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: Its correlation with disease activity. Cytokine 2006; 35: 148–153
   PubMed Web of Science ®Google Scholar
• Waszczykowska E, Robak E, Woźniacka A, Narbutt J, Torzecka JD, Sysa-Jędrzejowska A. Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation. Med Inflam 1999; 8: 93–100
   PubMed Web of Science ®Google Scholar
• Hrycek A, Cieślik P, Tustanowski J, Nowak S, Jedynak P. Selected serum cytokines in systemic lupus erythematosus treated with quinagolide. Lupus 2001; 10: 424–430
   PubMedGoogle Scholar
• Kadono T, Kikuchi K, Kubo M, Fujimoto M, Tamaki K. Serum concentrations of basic fibroblast growth factor in collagen diseases. J Am Acad Dermatol 1996; 35: 392–397
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-β by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998; 160: 2539–2545
   PubMed Web of Science ®Google Scholar
• Lu L-Y, Cheng H-H, Sung P-K, Shiue J, Chen A. Singlenucleotide polymorphisms of transforming growth factor-beta1 in Taiwanese patients with systemic lupus erythematosus. J Microbiol Immunol Infect 2004; 37: 145–152
   PubMedGoogle Scholar
• Hrycek A, Kuśmierz D, Dybała T, Świątkowska L. Expression of messenger RNA for transforming growth factor-beta1 and for transforming growth factor-beta receptors in peripheral blood of systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity 2007; 40: 23–30
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Gray JD, Stimmler MM, Horwitz DA. The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity. Lupus 1999; 8: 90–94
   PubMedGoogle Scholar
• Hrycek A, Siekiera U, Cieślik P, Szkróbka W. HLA-DRB1 and–DQB1 alleles and gene polymorphisms of selected cytokines in systemic lupus erythematosus. Rheumatol Int 2005; 26: 1–6
   PubMed Web of Science ®Google Scholar
• Capuano A, Constanzi S, Peluso G, Zannoni G, Vellone VG, Gremese E, Zoli A, Scott C, Beltrami CA, Romano G, Ferraccioli G. Hepatocyte growth factor and transforming growth factor β1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis Rheum 2006; 54: 3633–3639
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng N, Yin WH, Zhang B. Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004; 33: 340–343
   PubMedGoogle Scholar